The US patent law is about to undergo a major change with a raft of reforms set to be implemented. These changes are considered to be the most comprehensive since Congress passed the 1952 patent Act. But, the path has not been smooth, with voices of dissent materializing as the government carves out its plans.
MIP and Oblon, Spivak, McClelland, Maier & Neustadt jointly hosted a roundtable discussion – at a real roundtable – in Washington DC in late summer, to discuss some of those concerns and what really needs to be done
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has seemingly committed to hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left
Vaping dispute, in which Stobbs and Brandsmiths are the representatives, tested how the UK's Human Rights Act can apply to injunctions restraining unjustified threats